Affordable Access

Publisher Website

Triazole therapy for mucocutaneous candidiasis in HIV-infected patients

Authors
Publisher
Elsevier Inc.
Publication Date
Volume
9
Issue
5
Identifiers
DOI: 10.1016/s1055-3290(98)80031-9
Keywords
  • Hiv/Aids
  • Oropharyngeal Candidiasis
  • Esophageal Candidiasis
  • Triazole
  • Itraconazole
  • Fluconazole
Disciplines
  • Medicine

Abstract

Mucocutaneous candidiasis, such as oropharyngeal candidiasis, esophageal candidiasis, and vulvovaginal candidiasis, are common problems in patients with HIV infection. These conditions adversely affect patient quality of life and morbidity status. New oral triazole agents provide improved treatment options for patients with these and other opportunistic fungal infections; however, the development of resistance in some Candida species poses new challenges. This article provides an overview of the diagnosis of mucocutaneous candidiasis, current treatment modalities, concomitant drug interactions, common adverse drug reactions, and the emergence of fungal resistance, and it suggests nursing interventions to maximize patient benefits from antifungal therapy.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Triazole therapy for mucocutaneous candidiasis in...

on The Journal of the Association... 1998

Therapy for oropharyngeal candidiasis in HIV-infec...

on Journal of acquired immune def... December 1993

Frequency of oropharyngeal candidiasis in HIV-infe...

on Oral Surgery Oral Medicine Ora... Jan 01, 1999
More articles like this..